Early clinical promise for HCV antiviral combinations
09 November 2009
Asher Mullard
Please Login to read the full article.
09 November 2009
Asher Mullard
asher.mullard@informa.com
A combination of the nucleoside polymerase inhibitor RG7128 and the protease inhibitor RG7227 reduced viral load in a Phase I trial of hepatitis C virus patients, report InterMune, Pharmasset and Roche.
"This combination may represent the first [interferon]-free treatment regimen for both...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Gilead's single-tablet Quad regimen for HIV filed in the EU
- Inhibitex shares soar: HCV candidate shows "impressive" synergy with ribavirin; key PII data awaited
- Gilead's 2nd positive Phase III sets up early FDA submission for Quad
- Tibotec, Gilead in two potential deals for HIV combinations
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
